請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/61560完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 張上淳(Shan-Chwen Chang) | |
| dc.contributor.author | Chun-Kai Huang | en |
| dc.contributor.author | 黃俊凱 | zh_TW |
| dc.date.accessioned | 2021-06-16T13:05:52Z | - |
| dc.date.available | 2013-09-24 | |
| dc.date.copyright | 2013-09-24 | |
| dc.date.issued | 2013 | |
| dc.date.submitted | 2013-08-02 | |
| dc.identifier.citation | 1. Gerald L. Mandell JEB, Raphael Dolin. Mandell: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th ed. New york: Churchill Livingstone; 2009.
2. Munoz-Price LS, Weinstein RA. Acinetobacter infection. The New England journal of medicine 2008;358:1271-81. 3. Falagas ME, Karveli EA, Kelesidis I, Kelesidis T. Community-acquired Acinetobacter infections. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2007;26:857-68. 4. Kramer A, Schwebke I, Kampf G. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC infectious diseases 2006;6:130. 5. Joly-Guillou ML. Clinical impact and pathogenicity of Acinetobacter. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2005;11:868-73. 6. Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977-2000. Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2003;24:284-95. 7. Koljalg S, Naaber P, Mikelsaar M. Antibiotic resistance as an indicator of bacterial chlorhexidine susceptibility. The Journal of hospital infection 2002;51:106-13. 8. Kawamura-Sato K, Wachino J, Kondo T, Ito H, Arakawa Y. Reduction of disinfectant bactericidal activities in clinically isolated Acinetobacter species in the presence of organic material. The Journal of antimicrobial chemotherapy 2008;61:568-76. 9. Baltimore RS, Duncan RL, Shapiro ED, Edberg SC. Epidemiology of pharyngeal colonization of infants with aerobic gram-negative rod bacteria. Journal of clinical microbiology 1989;27:91-5. 10. Larson EL. Persistent carriage of gram-negative bacteria on hands. American journal of infection control 1981;9:112-9. 11. Glew RH, Moellering RC, Jr., Kunz LJ. Infections with Acinetobacter calcoaceticus (Herellea vaginicola): clinical and laboratory studies. Medicine 1977;56:79-97. 12. Goodhart GL, Abrutyn E, Watson R, Root RK, Egert J. Community-acquired Acinetobacter calcoaceticus var anitratus pneumonia. JAMA : the journal of the American Medical Association 1977;238:1516-8. 13. Anstey NM, Currie BJ, Hassell M, Palmer D, Dwyer B, Seifert H. Community-acquired bacteremic Acinetobacter pneumonia in tropical Australia is caused by diverse strains of Acinetobacter baumannii, with carriage in the throat in at-risk groups. Journal of clinical microbiology 2002;40:685-6. 14. Leung WS, Chu CM, Tsang KY, Lo FH, Lo KF, Ho PL. Fulminant community-acquired Acinetobacter baumannii pneumonia as a distinct clinical syndrome. Chest 2006;129:102-9. 15. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. American journal of infection control 2004;32:470-85. 16. Fagon JY, Chastre J, Domart Y, Trouillet JL, Gibert C. Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1996;23:538-42. 17. Lortholary O, Fagon JY, Hoi AB, et al. Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1995;20:790-6. 18. Seifert H, Baginski R, Schulze A, Pulverer G. Antimicrobial susceptibility of Acinetobacter species. Antimicrobial agents and chemotherapy 1993;37:750-3. 19. Li J, Rayner CR, Nation RL, et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrobial agents and chemotherapy 2006;50:2946-50. 20. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2006;12:826-36. 21. Urban C, Go E, Mariano N, et al. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. The Journal of infectious diseases 1993;167:448-51. 22. Jimenez-Mejias ME, Pachon J, Becerril B, Palomino-Nicas J, Rodriguez-Cobacho A, Revuelta M. Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1997;24:932-5. 23. Jellison TK, McKinnon PS, Rybak MJ. Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam. Pharmacotherapy 2001;21:142-8. 24. Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002;34:1425-30. 25. Tankovic J, Legrand P, De Gatines G, Chemineau V, Brun-Buisson C, Duval J. Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic typing methods. Journal of clinical microbiology 1994;32:2677-81. 26. Marques MB, Brookings ES, Moser SA, Sonke PB, Waites KB. Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations. Antimicrobial agents and chemotherapy 1997;41:881-5. 27. Bernabeu-Wittel M, Pichardo C, Garcia-Curiel A, et al. Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2005;11:319-25. 28. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Critical care (London, England) 2006;10:R27. 29. Kwa AL, Loh C, Low JG, Kurup A, Tam VH. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;41:754-7. 30. Rahal JJ. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;43 Suppl 2:S95-9. 31. Saballs M, Pujol M, Tubau F, et al. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. The Journal of antimicrobial chemotherapy 2006;58:697-700. 32. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. The Journal of antimicrobial chemotherapy 2008;61:1369-75. 33. Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2013;57:349-58. 34. Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. Journal of medical microbiology 2006;55:1619-29. 35. Bertrand X, Dowzicky MJ. Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial. Clinical therapeutics 2012;34:124-37. 36. Kuo SC, Chang SC, Wang HY, et al. Emergence of extensively drug-resistant Acinetobacter baumannii complex over 10 years: nationwide data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program. BMC infectious diseases 2012;12:200. 37. Betrosian AP, Frantzeskaki F, Xanthaki A, Georgiadis G. High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii. Scandinavian journal of infectious diseases 2007;39:38-43. 38. Levin AS, Levy CE, Manrique AE, Medeiros EA, Costa SF. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. International journal of antimicrobial agents 2003;21:58-62. 39. Motaouakkil S, Charra B, Hachimi A, et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. The Journal of infection 2006;53:274-8. 40. Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Critical care (London, England) 2005;9:R53-9. 41. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;36:1111-8. 42. Sobieszczyk ME, Furuya EY, Hay CM, et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. The Journal of antimicrobial chemotherapy 2004;54:566-9. 43. Wood GC, Hanes SD, Boucher BA, Croce MA, Fabian TC. Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia. Intensive care medicine 2003;29:2072-6. 44. Levin AS, Barone AA, Penco J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999;28:1008-11. 45. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrobial agents and chemotherapy 2003;47:2659-62. 46. Holloway KP, Rouphael NG, Wells JB, King MD, Blumberg HM. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit. The Annals of pharmacotherapy 2006;40:1939-45. 47. Koomanachai P, Tiengrim S, Kiratisin P, Thamlikitkul V. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2007;11:402-6. 48. del Mar Tomas M, Cartelle M, Pertega S, et al. Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2005;11:540-6. 49. Lee SO, Kim NJ, Choi SH, et al. Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study. Antimicrobial agents and chemotherapy 2004;48:224-8. 50. Anunnatsiri S, Tonsawan P. Risk factors and clinical outcomes of multidrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Thailand. The Southeast Asian journal of tropical medicine and public health 2011;42:693-703. 51. Kim YJ, Kim SI, Hong KW, Kim YR, Park YJ, Kang MW. Risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia: impact of appropriate antimicrobial therapy. Journal of Korean medical science 2012;27:471-5. 52. Mahgoub S, Ahmed J, Glatt AE. Underlying characteristics of patients harboring highly resistant Acinetobacter baumannii. American journal of infection control 2002;30:386-90. 53. Shih MJ, Lee NY, Lee HC, et al. Risk factors of multidrug resistance in nosocomial bacteremia due to Acinetobacter baumannii: a case-control study. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 2008;41:118-23. 54. Baran G, Erbay A, Bodur H, et al. Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2008;12:16-21. 55. Dent LL, Marshall DR, Pratap S, Hulette RB. Multidrug resistant Acinetobacter baumannii: a descriptive study in a city hospital. BMC infectious diseases 2010;10:196. 56. Maragakis LL, Cosgrove SE, Song X, et al. An outbreak of multidrug-resistant Acinetobacter baumannii associated with pulsatile lavage wound treatment. JAMA : the journal of the American Medical Association 2004;292:3006-11. 57. Carbonne A, Naas T, Blanckaert K, et al. Investigation of a nosocomial outbreak of extended-spectrum beta-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a hospital setting. The Journal of hospital infection 2005;60:14-8. 58. Simor AE, Lee M, Vearncombe M, et al. An outbreak due to multiresistant Acinetobacter baumannii in a burn unit: risk factors for acquisition and management. Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2002;23:261-7. 59. Wong TH, Tan BH, Ling ML, Song C. Multi-resistant Acinetobacter baumannii on a burns unit--clinical risk factors and prognosis. Burns : journal of the International Society for Burn Injuries 2002;28:349-57. 60. Smolyakov R, Borer A, Riesenberg K, et al. Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment. The Journal of hospital infection 2003;54:32-8. 61. Garnacho-Montero J, Ortiz-Leyba C, Fernandez-Hinojosa E, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive care medicine 2005;31:649-55. 62. Abbo A, Navon-Venezia S, Hammer-Muntz O, Krichali T, Siegman-Igra Y, Carmeli Y. Multidrug-resistant Acinetobacter baumannii. Emerging infectious diseases 2005;11:22-9. 63. Chen HP, Chen TL, Lai CH, et al. Predictors of mortality in Acinetobacter baumannii bacteremia. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 2005;38:127-36. 64. Wang JT, McDonald LC, Chang SC, Ho M. Community-acquired Acinetobacter baumannii bacteremia in adult patients in Taiwan. Journal of clinical microbiology 2002;40:1526-9. 65. Chen MZ, Hsueh PR, Lee LN, Yu CJ, Yang PC, Luh KT. Severe community-acquired pneumonia due to Acinetobacter baumannii. Chest 2001;120:1072-7. 66. Anstey NM, Currie BJ, Withnall KM. Community-acquired Acinetobacter pneumonia in the Northern Territory of Australia. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1992;14:83-91. 67. Kang SJ, Kang CI, Park SY, et al. Epidemiology and clinical features of community-onset Acinetobacter baumannii infections. Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2012;33:1053-5. 68. Falagas ME, Kasiakou SK, Rafailidis PI, Zouglakis G, Morfou P. Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. The Journal of antimicrobial chemotherapy 2006;57:1251-4. 69. Kwon KT, Oh WS, Song JH, et al. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. The Journal of antimicrobial chemotherapy 2007;59:525-30. 70. Wareham DW, Bean DC, Khanna P, et al. Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2008;27:607-12. 71. Metan G, Sariguzel F, Sumerkan B. Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia. European journal of internal medicine 2009;20:540-4. 72. Joung MK, Kwon KT, Kang CI, et al. Impact of inappropriate antimicrobial therapy on outcome in patients with hospital-acquired pneumonia caused by Acinetobacter baumannii. The Journal of infection 2010;61:212-8. 73. Kang CI, Chung DR, Peck KR, Song JH. Clinical predictors of Pseudomonas aeruginosa or Acinetobacter baumannii bacteremia in patients admitted to the ED. The American journal of emergency medicine 2012;30:1169-75. 74. Erbay A, Idil A, Gozel MG, Mumcuoglu I, Balaban N. Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. International journal of antimicrobial agents 2009;34:575-9. 75. Friedman ND, Kaye KS, Stout JE, et al. Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Annals of internal medicine 2002;137:791-7. 76. Chang TY, Lee CH, Liu JW. Clinical characteristics and risk factors for fatality in patients with bloodstream infections caused by glucose non-fermenting gram-negative Bacilli. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 2010;43:233-9. 77. Lin JN, Lai CH, Chen YH, et al. Characteristics and outcomes of polymicrobial bloodstream infections in the emergency department: A matched case-control study. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine 2010;17:1072-9. 78. Lee CC, Lee CH, Chuang MC, Hong MY, Hsu HC, Ko WC. Impact of inappropriate empirical antibiotic therapy on outcome of bacteremic adults visiting the ED. The American journal of emergency medicine 2012;30:1447-56. 79. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Critical care medicine 2003;31:1250-6. 80. Chen SJ, Chao TF, Chiang MC, et al. Predictors of mortality in surgical patients with Acinetobacter baumannii bacteremia. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 2011;44:209-14. 81. Seifert H, Strate A, Pulverer G. Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality. Medicine 1995;74:340-9. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/61560 | - |
| dc.description.abstract | 研究背景:
鮑氏不動桿菌常為伺機性感染,於院內感染與使用呼吸器病人居多。而臺灣近十年的研究指出,多重抗藥性鮑氏不動桿菌有上升的趨勢。雖然鮑氏不動桿菌為伺機性感染,但回顧論文指出,鮑氏不動桿菌也具有社區感染的潛力,只是目前相對於院內感染的研究,社區型研究的比例還是偏低。於臺大醫院急診處經細菌學檢驗為鮑氏不動桿菌菌血症中有25.2%為抗藥性菌株。因此本研究選擇進行急診鮑氏不動桿菌菌血症的研究,同時針對社區型鮑氏不動桿菌菌血症及多重抗藥性病株進行分析。 研究目的: 分析急診就診病人感染之社區型、醫療照護型及院內感染的鮑氏不動桿菌菌血症之差異 感染多重抗藥性鮑氏不動桿菌菌血症之危險因子分析 鮑氏不動桿菌菌血症之死亡因子分析 經驗性抗生素與治療結果的關聯性 研究設計、地點及對象: 本研究收納自2008年1月1日到2012年12月31日期間到國立臺灣大學醫學院附設醫院急診室就診的病人,研究對象為細菌學檢驗發現血液培養有鮑氏不動桿菌之成年病人。 研究方法: 收入於急診血液培養為鮑氏不動桿菌菌血症的病人,以病歷回顧的方式進行分析。所收集的資料分成三個區塊,分別是鮑氏不動桿菌菌血症發作前、發作時及發作後。發作前以病人的基本資料、潛在性疾病為主,發作時以臨床表徵、實驗數值紀錄及藥物治療為主,發作後記錄病人的預後。以發病後第三十天的死亡率做為治療結果的評估,也有紀錄第七天、第十四天以及出院時的死亡率做為分析。此外,也針對非多重抗藥性與多重抗藥性菌株之病人資料進行比較。統計方法包含單變項及多變項的羅吉斯回歸分析,對於存活分析以Log-rank進行比較,統計分析的工具以Microsoft Excel 2013及SAS(9.3版)進行資料處理。 研究結果: 本研究中,122位病人共發生123個菌血症事件,有78個事件為單一菌種菌血症;整體病人的平均年齡為66歲,男性比例為61%;病人的Charlson’s comorbidity index為3.4±2.5、Pitt bacteremia score為 2.1±2.4,發生敗血性休克的比例為23.6%,過去一個月內有使用過抗生素的比例為34.2%;經驗性治療使用合併抗生素治療者只有10例,而確切性治療使用合併抗生素治療者也只有12例。多重抗藥性菌血症占了25.2%,全部123個菌血症及78個單一菌種菌血症個案於菌血症發作後的第三十天死亡率分別為19.7%及16.9%。 對單一菌種而言,經驗性使用之單一或合併抗生素治療屬適當者分別為45.8%及50.0%,並沒有達到統計上顯著的差異(P=1.000)。而經驗性單一或合併抗生素對於第七天、第十四天及第三十天之死亡率都沒有達到統計上顯著差異。 由多變項羅吉斯回歸分析發現,整體病人感染多重抗藥性鮑氏不動桿菌之危險因子,包含:護理之家住民(OR 23.49,P=0.0004)、腎臟病末期病人(OR 12.78,P=0.0107)、住加護病房者(OR 3.57,P=0.0473)、癌症病人(OR 0.206,P=0.0089);而其中單一菌種菌血症,則包含:護理之家住民(OR 33.74,P=0.0002)、住加護病房者(OR 6.188,P=0.0305)、過去一個月內有動過手術者(OR 21.60,P=0.0192)。 對於第三十天之死亡率,經由多變項羅吉斯回歸分析,就全體病人而言,影響第三十天之死亡危險因子,包含了敗血性休克(OR 10.828,P<0.0001)及多重抗藥性菌株(OR 3.419,P=0.0259);就單一菌種菌血症病人而言,影響第三十天死亡之危險因子也包含了敗血性休克(OR 9.618,P=0.0019)及多重抗藥性菌株(OR 6.06,P=0.0161);而對於社區型發作型之病人而言,其預後因素只有敗血性休克(OR 6.216,P=0.0018)。經驗性抗生素合併與否及經驗性抗生素治療適當與否,對於預後沒有達到統計上顯著差異。 結論 於本研究中,第三十天死亡率與多重抗藥性與敗血性休克有關;此外,住在護理之家、住在加護病房、過去一個月內有動過手術為多重抗藥性鮑氏不動桿菌菌血症之危險因子。經驗性抗生素適當與否或經驗性抗生素合併與否,於菌血症發作後第三十天死亡率並無顯著影響。 | zh_TW |
| dc.description.abstract | Background:
Acinetobacter baumannii infections play an important role in opportunistic infection. They have become common in hospitalized patients or patients on mechanical ventilator. According to a longitudinal surveillance on A. baumanniiin Taiwan, the number of multidrug resistant(MDR)strain has climbed gradually over the last decade. Although A. baumannii infections were considered opportunistic, they could cause community-acquired infection with rare occasions. A. baumannii bacteremia cultured in the emergency department(ED)at National Taiwan University Hospital exhibited 25.2 % with MDR strains. Therefore, it is essential to conduct a study in ED patients to analyze the clinical characteristics of the community-acquired A.baumannii infections and multidrug resistance. Study objective: 1. To discover the differences between community-acquired infections, healthcare-associated infections and nosocomial infections. 2. To identify risk factors of MDR resistant A. baumannii bacteremia in the emergent department. 3. To analyze prognostic factors of 30 day(D30)mortality of A. baumannii bacteremia 4. To evaluate the correlation between empirical antibiotics and treatment outcome Study location、design and study population A retrospective study was conducted in National Taiwan University Hospital. Patients with A. baumannii bacteremia visiting ED between January 2008 and December 2012 were identified from the medical records of the clinical microbiology laboratory. Methods Data were collected from medical charts and the hospital computerized database. Data retrieved for each patient included patients’ demographic profiles, underlying diseases, previous A. baumannii infection or colonization history, clinical presentation, antibiotics regimens at onset of bacteremia, management and clinical response after bacteremia. The primary endpoint was D30 all-cause mortality. Risk factors of MDR A. baumannii bacteremia were also analyzed. Risk factors and clinical outcomes were examined using univariate analysis and multivariate logistic regression analysis. Survival curves shown by Kaplan-Meier method were compared with Log-rank test. Microsoft 2013 and SAS(ver. 9.3)were used for data management. Result One hundred and twenty three episodes in 122 patients were included in this study. Among them, 78 were monomicrobial infections and 45 were polymicrobial infections. Patients’ average age was 66 years old, and 61% of them were male. The average Charlson’s comorbidity index was 3.4±2.5. Previous exposure to antibiotics within 1 month was 34.2%. Patients’ average Pitt bacteremia scores were 2.1±2.4. There were 85.4% episodes presenting sepsis with 28.6% of septic shock. Empirical combination therapy was given only in 10 episodes (8.4%)and definitive combination therapy was used in 12 episodes (11.5%).There were 31 (25.2%)A. baumannii episodes. The overall D30 mortality was 19.7%. It was 16.9% for monomicrobial infections. Empirical monotherapy and combination therapy provided comparably adequate therapy(45.8% vs. 50.0 %, P=1.0000)with similar D30 mortality in each regimen (0% vs. 18.1%, P=1.000). Multivariate logistic regression model identified the following variables as significant independent risk factors for monomicrobial MDR A. baumannii bacteremia: nursing home residents(OR 33.74, P=0.0002), intensive care unit stay (OR 6.188, P=0.0305)and surgery within 1 month(OR 21.60, P=0.0192). Following factors were independently associated with D30 mortality in monomicrobial group: septic shock(OR 9.618, P=0.0019)and multi-drug resistant pathogen(OR 6.06, P=0.0161).Empirical therapy was not significantly associated with mortality in all patients and monomicrobial group. Conclusion: Septic shock and MDR bacteremia were significantly associated with D30 mortality in patients with A.baumannii bacteremia in the ED. Living in the nursing home, ICU stay, surgery within 1 month played important roles in acquisition of MDR A. baumannii in these patients. Empirical treatment did not affect mortality of A.baumannii bacteremia. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T13:05:52Z (GMT). No. of bitstreams: 1 ntu-102-R00451009-1.pdf: 3379052 bytes, checksum: 80f8843b88d6d8eed848d58e77568cb1 (MD5) Previous issue date: 2013 | en |
| dc.description.tableofcontents | 誌謝 ii
中文摘要 iii Abstract vi 目錄 ix 圖目錄 xi 表目錄 xii 第一章 前言 1 第二章 文獻探討 2 第1節 細菌學 2 第2節 流行病學 2 第3節 鮑氏不動桿菌之感染 3 二.3.1臨床表徵 (clinical manifestations) 3 第4節 鮑氏不動桿菌之抗藥性 5 第5節 鮑氏不動桿菌之治療準則 6 第6節 抗藥性鮑氏不動桿菌之趨勢 7 第7節 社區型鮑氏不動桿菌感染 15 第8節 經驗性抗生素治療適當與否與預後之關係 19 第9節 鮑氏不動桿菌菌血症之死亡危險因子 21 第三章 研究目的 25 第四章 研究方法 26 第1節 研究架構 26 第2節 研究地點及研究對象 27 第3節 資料收集 27 第4節 名詞定義 29 第5節 細菌檢體採集 32 第6節 治療結果評估 32 第7節 統計方法 33 第五章 研究結果 34 第1節 描述性統計 34 第2節 院內感染、醫療照護及社區感染差異 54 第3節 感染多重抗藥性鮑氏不動桿菌之單變項統計分析 60 第4節 感染多重抗藥性鮑氏不動桿菌之多變項統計分析 74 第5節 存活曲線 75 第6節 死亡危險因子之單變項統計分析 79 第7節 死亡危險因子之多變項統計分析 100 第六章 討論 101 第1節 感染鮑氏不動桿菌之病人族群 101 第2節 抗生素治療 101 第3節 個別抗生素之研究 103 第4節 比較社區型、醫療照護及院內感染之差異 104 第5節 感染多重抗藥性鮑氏不動桿菌之危險因子 105 第6節 死亡率分析 107 第7節 死亡之危險因子 108 第8節 研究限制 110 第七章 結論 111 第八章 參考資料 112 附錄 個案報告表 121 | |
| dc.language.iso | zh-TW | |
| dc.subject | 急診 | zh_TW |
| dc.subject | 鮑氏不動桿菌 | zh_TW |
| dc.subject | 菌血症 | zh_TW |
| dc.subject | 多重抗藥性鮑氏不動桿菌 | zh_TW |
| dc.subject | 預後因子 | zh_TW |
| dc.subject | prognostic factor | en |
| dc.subject | Acinetobacter baumannii | en |
| dc.subject | bacteremia | en |
| dc.subject | multidrug resistant Acinetobacter baumannii | en |
| dc.subject | emergency department | en |
| dc.title | 急診鮑氏不動桿菌菌血症感染病人之處方型態分析:預後因子與治療結果 | zh_TW |
| dc.title | Retrospective study of Acinetobacter baumannii bacteremia in emergency department: prognosis and clinical outcome | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 101-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.coadvisor | 林淑文(Shu-Wen Lin) | |
| dc.contributor.oralexamcommittee | 林慧玲(Fe-Lin Lin Shao),王振泰(JANN-TAY WANG) | |
| dc.subject.keyword | 急診,鮑氏不動桿菌,菌血症,多重抗藥性鮑氏不動桿菌,預後因子, | zh_TW |
| dc.subject.keyword | emergency department,Acinetobacter baumannii,bacteremia,multidrug resistant Acinetobacter baumannii,prognostic factor, | en |
| dc.relation.page | 134 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2013-08-02 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
| 顯示於系所單位: | 臨床藥學研究所 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-102-1.pdf 未授權公開取用 | 3.3 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
